awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
Graphs
1
Q50858454-5C037BDC-EB02-439E-B036-2B32C917D8EC
Q50858454-5C037BDC-EB02-439E-B036-2B32C917D8EC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50858454-5C037BDC-EB02-439E-B036-2B32C917D8EC
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
P2860
Q50858454-5C037BDC-EB02-439E-B036-2B32C917D8EC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50858454-5C037BDC-EB02-439E-B036-2B32C917D8EC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1269e5fd2eb230588d1f4487f8eb97a1d0fbe18d
P2860
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.